December 2003

Got Life? Corporate lawyers haven’t had much to celebrate since the Internet bubble burst, but a recent stock market run on life sciences companies is breathing new buoyancy into some practices.

Amgen’s Cannibalistic Ways If you don’t think that Amgen is excited about its future, check out what the company is piling on its plate. The biotech giant will be earmarking half of next year’s revenue to launch a $5 billion share buyback.

Boston’s Biotech Moment The future is moving out of dusty library stacks and into pristine laboratories on both sides of the Charles River, making this area the national leader in biotechnology. The boom is driven by a new breed of intellectual wearing a white lab coat and using science to breach the barrier between academia [...]

Tech Transfer: The Ties That Bind Did you know that the lack of an IPO window, depressed market conditions and a downturn in venture financing affect not only companies but also universities? That’s because so many academic institutions are tied to the fortunes of companies, both small and large, through their technology transfer agreements.